Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
Date:12/8/2008

WILMINGTON, Del. and WINSTON-SALEM, N.C., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and Targacept, Inc. today announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

AZD3480 did not meet the trial's criteria for statistical significance on the primary endpoints, improvement on various cognitive domains measured by the IntegNeuro computerized test battery. AZD3480 was generally well tolerated in the study. AstraZeneca and Targacept do not expect to progress AZD3480 into Phase III studies for CDS.

In addition to the HALO trial, AstraZeneca and Targacept previously announced top-line results from a Phase IIb study of AZD3480 in mild to moderate Alzheimer's disease, known as the Sirocco trial, and are currently evaluating AZD3480 in a Phase II exploratory study in attention deficit/hyperactivity disorder (ADHD) in adults. A decision by AstraZeneca with respect to potential further development of AZD3480 in Alzheimer's disease or ADHD is now expected in the first half of 2009, pending completion of the adult ADHD study and other ongoing evaluations.

"While this trial outcome did not meet our objectives, we continue to pursue medicines that target neuronal nicotinic receptors (NNRs) with Targacept to treat cognitive disorders," said Bob Holland, Vice President and Head of the Neuroscience Therapy Area, AstraZeneca.

Targacept and AstraZeneca also announced that the lead compound arising out of the parties' preclinical research collaboration is poised to enter the clinic. AstraZeneca plans by the end of 2008 to initiate a Phase I trial of AZD1446 (TC-6683), a product candidate selective for the alpha4beta2 NNR. Under the terms of the parties' collaborat
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
2. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
3. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
4. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
5. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
6. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
7. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
10. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... of multiple strains of cannabis and European Union ... select the best strains for development of proprietary ... cannabis formulations to market for critical ailments such ...
(Date:7/31/2014)... , July 31, 2014 For the first ... watch the implantation of the SynCardia temporary Total Artificial ... matching video posted on the Journal of Visualized Experiments ... read the paper on the SynCardia Total Artificial Heart ... video accompanies "Implantation of the SynCardia Total Artificial Heart," ...
(Date:7/31/2014)... 2014 TB Alliance, a not-for-profit with ... and affordable treatments, announced the appointment of ... Affairs. Mr. Brock comes to TB Alliance having ... Relations for WWF International (formerly known as the ... will guide the TB Alliance,s resource development, advocacy ...
Breaking Medicine Technology:Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... post-surgery hormone therapy reduced risk of breast cancer return ... First Phase III data to substantiate anticancer effect of ... prevention of bone complications due to bone metastases, with ... Feb. 11 /PRNewswire/ -- A newly published ...
... test to help guide treatment decisionsANN ARBOR, Mich., Feb. ... Comprehensive Cancer Center have identified a panel of ... prostate cancer.The finding could lead to a simple test ... slow-growing and which require immediate, aggressive treatment.Results of the ...
Cached Medicine Technology:Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 2Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 3Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 4Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 5Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 6Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 7Researchers Discover Metabolite Linked to Aggressive Prostate Cancer 2Researchers Discover Metabolite Linked to Aggressive Prostate Cancer 3
(Date:7/31/2014)... -- A class of medications previously linked to ... negatively affect their physical functioning according to investigators ... Center for Aging Research, the University of East ... In a systemic review of more than a ... with anticholinergic properties, they report that these drugs ...
(Date:7/31/2014)... application of vacuum pressure is a promising approach to ... an experimental study in the August issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , "Mechanical ... area of the brainshows promise as a safe and ...
(Date:7/31/2014)... Las Vegas, Nevada (PRWEB) July 31, 2014 ... to provide next generation authentication services to cloud service ... way to utilize hardware protected multi-factor authentication with online ... the Internet's reliance on password-based authentication. It is the ... data breaches taking place around the globe. Instead of ...
(Date:7/31/2014)... 31, 2014 The Beryl Institute announces ... Board and four new members of its ... as the global community of practice and premier thought ... , Executive board members are industry leaders who advise ... valuable insight into market and industry trends. The advisory ...
(Date:7/31/2014)... Web Programming Services, a business partner of ... firm, has recently launched a new service named as ... for everyone, the company has announced a very nominal ... Programming Services has tailored the service after doing a ... likely expectations of the clients from their designers. This ...
Breaking Medicine News(10 mins):Health News:Common drugs adversely impair older adults' physical as well as cognitive functioning 2Health News:Vacuum treatment may limit damage after traumatic brain injury 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2
... INDIANAPOLIS, Feb. 18 The Board of Directors of Eli ... Ralph Alvarez as a new member, effective April 1, 2009. ... of McDonald,s Corporation and is also a member of McDonald,s ... will serve on both the board,s finance committee and public ...
... Fla., Feb. 18 On March 2, 2009 at ... Florida will become Herzing University at a sign-changing event ... T-shirts and donating the profits to the American Cancer ... Heather Antonacci.This event represents the 44-year evolution of a ...
... R.I., Feb. 18 CVS Caremark Corporation (NYSE: ... into an agreement with the U.S. Federal Trade Commission ... Services Office for Civil Rights (OCR) concerning disposal of ... agreement resolves an investigation prompted by media reports from ...
... HOUSTON (Feb. 18, 2009) The fight ... will soon receive a boost from an ultrasound ... technology under development will allow early prediction of ... of fracture healing. , National Space Biomedical Research ...
... MeasuresWASHINGTON, Feb. 18 Patients across the United ... technology (HIT) law providing comprehensive privacy and security ... for psychotherapy records. The Health Information Technology for ... the economic stimulus package, was passed by the ...
... eligibility serviceFORT WORTH, Texas, Feb. 18 eRx ... services to the retail pharmacy industry, has announced ... solution, eRx CardFinder. The exclusive service, which was ... than 14,000 pharmacies nationwide."We place high significance on ...
Cached Medicine News:Health News:Ralph Alvarez Elected to Lilly Board of Directors 2Health News:Herzing College, Orlando Will Change Name to Herzing University and Host Sign-Changing Event on March 2, 2009 2Health News:Herzing College, Orlando Will Change Name to Herzing University and Host Sign-Changing Event on March 2, 2009 3Health News:CVS Caremark Issues Statement on Settlement Concerning Disposal of Patient Information at its Retail Stores 2Health News:SCAN: Delivering bone disorder diagnosis, fracture healing 2Health News:SCAN: Delivering bone disorder diagnosis, fracture healing 3Health News:Patients Gain Protections in Health Information Technology Law 2Health News:Patients Gain Protections in Health Information Technology Law 3Health News:eRx Network(R) Expands eRx CardFinder(TM) Reach 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: